Replies to post #6580 on Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

With the trial apparently filling quickly, there is apparent demand/need/requirement for the drug. At some point, more testing is pointless, and addressing the demand could catch attention of the FDA.

Plus the phase I data is still accumulating.


If the trial/approval (even partial) could be shortened by 6-12 months, so much the better.